KRM Ayurveda Ltd H2 FY26: Revenue Hits ₹100 Crore Milestone as PAT Surges 149%—Is This the Herb-Infused Multibagger?

1. At a Glance

Forget your standard pharmaceutical plays for a second. We are looking at a company that is trying to turn the ancient science of Ayurveda into a high-margin, scalable, and digital-first healthcare machine. KRM Ayurveda Ltd just dropped its FY26 numbers, and they are, quite frankly, loud. This isn’t just about selling herbal powders; it’s an integrated platform that connects multispecialty hospitals, clinics, teleconsultations, and in-house manufacturing.

The company just crossed the ₹100 Crore Revenue milestone in FY26. To put that in perspective, they’ve managed to grow their sales by over 32% in a year where many healthcare players were struggling with rising costs. But the real kicker? Their PAT (Profit After Tax) surged by nearly 149% in H2 FY26 compared to H2 FY25.

We are seeing a massive shift in the business model. In FY23, they were basically a product company (93% products). Fast forward to FY26, and Services (Hospitals/Clinics) now contribute 63.21% of the revenue. This is the classic “razor and blade” model but with a Zen twist: the hospitals provide the high-value services, and the in-house medicines keep the margins fat.

The company listed in January 2026, raising ₹72 Crores to fuel a massive expansion into telemedicine and CRM infrastructure. With a Market Cap of ₹503 Crore, it’s still in the “detective” territory for small-cap hunters. The question is: is this a sustainable wellness revolution or just a post-IPO sugar rush?

2. Introduction

KRM Ayurveda was incorporated in late 2019, right before the world decided that “immunity” was the only currency that mattered. While most Ayurveda brands focus on selling honey and chyawanprash on Amazon, KRM took the harder, more capital-intensive route: Hospitals.

They started with a focus on kidney care—a niche that is notoriously difficult to treat and has a massive, underserved patient base in India. From there, they’ve branched out into chronic disease management, lifestyle disorders, and post-treatment rehab.

What makes them interesting is the geographical mix. They aren’t just a local Delhi play anymore. While Delhi and Haryana still account for over 56% of their revenue, they’ve managed to crack the US market, which now accounts for 34% of their sales through exports and teleconsultations. That’s a massive margin booster right there.

The management, led by Dr. Puneet Dhawan, seems to be playing the long game. They’ve moved from 2 hospitals to 6 hospitals and 5 clinics in a short span. They have 223+ beds and a growing army of 40 physicians. This is no longer a small family clinic; it’s a corporate entity trying to institutionalize Ayurveda.

3. Business Model – WTF Do They Even Do?

Imagine a hospital where instead of just pumping you with chemicals, they use Panchakarma (the five-fold detoxification process) and Shirodhara (dripping oil on your forehead until you forget your mortgage).

The Integrated Ecosystem:

1. The Hospitals (IPD/OPD): This is the “Service” arm. They have 6 facilities, including a massive 95-bed flagship in Gurgaon. They handle everything from kidney issues to stress management.
2. The Manufacturing (The Pharmacy): They have a unit in Kundli, Haryana. They don’t just prescribe medicines; they make them. This keeps the supply chain tight and the margins high.
3. Telemedicine: This is their growth engine. It’s how they reached the US market. You get a consultation in New York and buy medicines made in Haryana.
4. B2B Tie-ups: They’ve signed up with big boys like Hero MotoCorp, SBI General Insurance, and Future Generali for cashless treatments. This ensures a steady flow of “institutional” patients who don’t haggle over bills.

In simple terms: They find you through digital marketing or insurance tie-ups, treat you in their specialty hospitals, and then keep you on their proprietary medicines for the long haul. It’s a closed-loop system that would make a software SaaS founder blush.

4. Financials Overview

The company reports results on a Half-Yearly basis. Based on the latest release for H2 FY26 (the period ending March 31, 2026), here is how the numbers stack up.

Key Performance Indicators (₹ in Crores)

*Adjusted for equity expansion where applicable.

Witty Commentary: > EBITDA margins jumped from 21.6% to 33.5% in a year. That’s not just growth; that’s a surgical strike on inefficiency. The management “walked the talk” from their IPO prospectus—they promised scale, and they delivered a 30% jump in the top line while doubling the bottom line.

Annualised EPS Calculation:

Since the latest result is H2 FY26 (Half-Yearly), and we have the full year’s PAT of ₹20.12 Cr:

• Total Annual EPS = ₹9.46 (As per the latest full-year audited data).

Are you paying attention to the margin expansion, or are you too busy looking at the “Ayurveda” label and thinking it’s low-tech?

5. Valuation Discussion – Fair Value Range

Let’s get our hands dirty with some math.

Method 1: P/E Multiple

• Current EPS: ₹9.46
• Industry Average P/E: 29.7
• KRM Current P/E: 25.0
• Conservative Valuation (25x): $9.46 \times 25 = ₹236.50$